Table 2.
Cox proportional hazards multivariate analysis of cancer-specific survival in demographical, histological/clinic-pathological variables, and in rs1805363, rs13447623 and 3′ UTR rare variants
| Covariates | HR (95% CI) | P-valuea | ||
|---|---|---|---|---|
| Age at diagnosis (years) | 1.01 (0.98–1.04) | 0.61 | ||
| Gender (male versus female) | 0.72 (0.39–1.31) | 0.28 | ||
| T stage (increasing stage) | 1.50 (0.98–2.30) | 0.06 | ||
| N stage (increasing stage) | 1.96 (0.88–4.37) | 0.10 | ||
| Histological grade (increasing grade) | 1.12 (0.50–2.48) | 0.79 | ||
| Hydronephrosis (yes versus no) | 1.21 (0.66–2.22) | 0.53 | ||
| Neoadjuvant/concurrent chemotherapy (yes versus no) | 0.52 (0.22–1.20) | 0.12 | ||
| Variant (observed MAF) | Genotype | N | ||
| rs1805363 G > A (0.11) | GG | 152 | 1 | 0.001 |
| AG | 28 | 1.49 (0.80–2.78) | ||
| AA | 6 | 8.00 (2.93–21.90) | ||
| rs13447623 A > G (0.25) | AA | 110 | 1 | 0.05 |
| AG | 62 | 0.86 (0.50–1.49) | ||
| GG | 14 | 3.68 (1.78–7.60) | ||
| Joint two-SNP analysis | ||||
| rs1805363 G > A | 2.19 (1.12–4.30) | 0.02 | ||
| rs13447623 A > G | 0.95 (0.54–1.66) | 0.86 | ||
| Rare variants collapsed analysis | ||||
| No 3′ UTR rare variants | 179 | 1 | 0.009 | |
| 1+ 3′ UTR rare variants | 7 | 4.04 (1.42–11.51) | ||
aSignificant P-values of <0.05 are in bold.